RT Journal Article
SR Electronic
T1 Hepatitis C virus recurrence after liver transplantation
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP 575
OP 578
DO 10.1136/gut.44.4.575
VO 44
IS 4
A1 BIZOLLON, T
A1 DUCERF, C
A1 TREPO, C
A1 MUTIMER, D
YR 1999
UL http://gut.bmj.com/content/44/4/575.abstract
AB Cirrhosis due to hepatitis C virus (HCV) is now the most common indication of liver transplantation in Western Europe and the United States. In the absence of effective prophylaxis, recurrent HCV infection is almost inevitable. Though the natural history and intermediate term outcome of recurrent HCV are now better documented, those factors which may influence the recurrence of hepatitis and consequent progression of graft disease remain unclear. Interferon (IFN) as a sole agent for the treatment of recurrent infection has proved unsatisfactory. Early intervention with a combination of IFN and ribavirin seems promising, and this approach may prevent or delay progression of HCV related graft disease after liver transplantation.HCVhepatitis C virusIFNinterferonHBVhepatitis B virusCMVcytomegalovirus